Internalisation of the bleomycin molecules responsible for bleomycin toxicity: a receptor-mediated endocytosis mechanism.

作者: Géraldine Pron , Nawel Mahrour , Stéphane Orlowski , Omar Tounekti , Bruno Poddevin

DOI: 10.1016/S0006-2952(98)00282-2

关键词:

摘要: Bleomycin (BLM) does not diffuse through the plasma membrane but nevertheless displays cytotoxic activity due to DNA break generation. The aim of study was describe mechanism BLM internalisation. We previously provided evidence for existence BLM-binding sites at surface DC-3F Chinese hamster fibroblasts, as well their involvement in cytotoxicity on cells and related BLM-resistant sublines. Here we report that A253 human subline C-10E also possessed a protein ca. 250 kDa specifically binding BLM. Part this cell resistance could be explained by decrease number exposed with respect cells. comparison between exposing similar revealed faster fluid phase endocytosis, greater sensitivity Moreover, experimental modification endocytotic vesicle size showed directly correlated flux area engulfed during endocytosis rather than volume incorporated. Thus, would internalised receptor-mediated which first require its receptor then transfer complex into intracellular vesicles, followed entry cytosol, probably from nonacidic compartment.

参考文章(32)
Sjur Olsnes, Kirsten Sandvig, Entry of Polypeptide Toxins into Animal Cells Springer, Boston, MA. pp. 195- 234 ,(1985) , 10.1007/978-1-4615-6904-6_7
Lazo Js, Newman Ra, Meandzija B, Labaree Dc, Schisselbauer Jc, Braun Id, Kennedy Ka, Characteristics of Bleomycin-resistant Phenotypes of Human Cell Sublines and Circumvention of Bleomycin Resistance by Liblomycin Cancer Research. ,vol. 49, pp. 185- 190 ,(1989)
T Takeuchi, K Maeda, H Umezawa, Y Okami, New antibiotics, bleomycin A and B. The Journal of Antibiotics. ,vol. 19, pp. 200- 209 ,(1966)
Stéphane Orlowski, Jean Belehradek, Claude Paoletti, Lluis M. Mir, Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochemical Pharmacology. ,vol. 37, pp. 4727- 4733 ,(1988) , 10.1016/0006-2952(88)90344-9
Susan Band Horwitz, Samar N. Roy, Characterization of the association of radiolabeled bleomycin A2 with HeLa cells Cancer Research. ,vol. 44, pp. 1541- 1546 ,(1984)
R T Dean, W Jessup, C R Roberts, Effects of exogenous amines on mammalian cells, with particular reference to membrane flow. Biochemical Journal. ,vol. 217, pp. 27- 40 ,(1984) , 10.1042/BJ2170027
Michel Belehradek, Christian Domenge, Bernard Luboinski, Stéphane Orlowski, Jean Belehradek, Lluis M. Mir, Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial. Cancer. ,vol. 72, pp. 3694- 3700 ,(1993) , 10.1002/1097-0142(19931215)72:12<3694::AID-CNCR2820721222>3.0.CO;2-2
L.M. Mir, O. Tounekti, S. Orlowski, Bleomycin: revival of an old drug. General Pharmacology-the Vascular System. ,vol. 27, pp. 745- 748 ,(1996) , 10.1016/0306-3623(95)02101-9
Richard Heller, Mark J. Jaroszeski, L. Frank Glass, Jane L. Messina, David P. Rapaport, Ronald C. DeConti, Neil A. Fenske, Richard A. Gilbert, Lluis M. Mir, Douglas S. Reintgen, Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy Cancer. ,vol. 77, pp. 964- 971 ,(1996) , 10.1002/(SICI)1097-0142(19960301)77:5<964::AID-CNCR24>3.0.CO;2-0